While targeting IAPs presents a promising therapeutic strategy, there are several challenges involved. One major challenge is the potential for toxicity, as IAPs are also involved in normal cellular processes. Additionally, cancer cells may develop resistance to IAP inhibitors through various mechanisms, such as upregulation of alternative survival pathways. Therefore, ongoing research is focused on understanding the complex roles of IAPs in different tissues and developing more selective and effective inhibitors.
